天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600161 天坛生物

已收盘 10-09 15:00:00

{"stockData":{"symbol":"600161","market":"SH","secType":"STK","nameCN":"天坛生物","latestPrice":12.73,"timestamp":1791529200000,"preClose":12.55,"halted":0,"volume":18801151,"delay":0,"changeRate":0.0143,"floatShares":1977000000,"shares":1977000000,"eps":0.383,"marketStatus":"已收盘","change":0.18,"latestTime":"10-09 15:00:00","open":12.51,"high":12.86,"low":12.51,"amount":239000000,"amplitude":0.0279,"askPrice":12.73,"askSize":400,"bidPrice":12.72,"bidSize":22,"shortable":0,"etf":0,"ttmEps":0.383,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.55,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":13.81,"lowLimit":11.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1977371446,"isCdr":false,"pbRate":2.11,"roa":"--","peRate":33.237598,"roe":"2.51%","epsLYR":0.55,"committee":-0.525492,"marketValue":25172000000,"turnoverRate":0.0095,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-12。","floatMarketCap":25172000000},"requestUrl":"/m/hq/s/600161/wiki","defaultTab":"wiki","newsList":[{"id":"2673003942","title":"天坛生物（600161）披露下属企业获得人凝血因子ⅨⅢ期临床试验总结报告，10月08日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673003942","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673003942?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:14","pubTimestamp":1791468861,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，天坛生物报收于12.55元，较前一交易日下跌0.32%，最新总市值为248.16亿元。近日，天坛生物发布《关于下属企业获得临床试验总结报告的公告》。公告显示，公司下属成都蓉生药业有限责任公司研制的人凝血因子Ⅸ已完成Ⅲ期临床试验并取得临床试验总结报告。临床试验结果显示，药物主要PK参数与已上市同类产品相似，能有效提升患者凝血因子Ⅸ水平，改善出血症状，且具有良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0185","BK0082","BK0188","BK0168","BK0028","600161","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673504076","title":"天坛生物(600161.SH)下属企业获得人凝血因子Ⅸ临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2673504076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673504076?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:34","pubTimestamp":1791455673,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天坛生物(600161.SH)发布公告，近日，公司下属成都蓉生药业有限责任公司(简称“成都蓉生”)研制的“人凝血因子Ⅸ”完成了Ⅲ期临床试验并取得临床试验总结报告。据悉，成都蓉生生产的人凝血因子Ⅸ临床试验结果显示，该药物主要PK参数与同类已上市产品的数据相似，输注后能有效提升血友病B患者的凝血因子Ⅸ水平，提高血友病B患者的凝血功能，改善血友病B患者的出血症状和体征，可有效控制血友病B患者的出血。同时安全性结果显示，本品在临床应用过程中对血友病B患者具有良好的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK0028","600161","BK0168","BK0239","BK0185","IBBQ","MDTX","BK0010","PSYK","BK0046","BK0082","BMED","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671664942","title":"天坛生物（600161）9月28日主力资金净买入303.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671664942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671664942?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:23","pubTimestamp":1790641414,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，天坛生物报收于12.22元，上涨0.99%，换手率0.42%，成交量8.39万手，成交额1.02亿元。近5日资金流向一览见下表：天坛生物融资融券信息显示，融资方面，当日融资买入580.09万元，融资偿还842.88万元，融资净偿还262.79万元。天坛生物主营业务：以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0185","BK0082","BK0188","BK0168","BK0028","600161","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667076905","title":"每周股票复盘：天坛生物（600161）四家浆站获采浆许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667076905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667076905?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:59","pubTimestamp":1789235948,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，天坛生物报收于12.09元，较上周的12.28元下跌1.55%。本周，天坛生物9月9日盘中最高价报12.76元。本周关注点来自公司公告汇总：皋兰、永登、甘谷、金塔四家下属浆站获单采血浆许可证，有助于扩大原料血浆采集规模。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0185","BK0188","BK0168","BK0010","BK0239","BK0046","600161","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665832169","title":"天坛生物（600161）披露下属浆站获得单采血浆许可证公告，9月8日股价上涨3.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665832169","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665832169?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:00","pubTimestamp":1788861618,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，天坛生物报收于12.73元，较前一交易日上涨3.92%，最新总市值为251.72亿元。近日，天坛生物发布关于下属浆站获得单采血浆许可证的公告。公告显示，公司控股子公司国药集团兰州生物制药有限公司下属皋兰兰生单采血浆有限责任公司、永登兰生单采血浆有限责任公司、甘谷兰生单采血浆有限责任公司、金塔兰生单采血浆有限责任公司收到甘肃省卫生健康委员会签发的《单采血浆许可证》，上述浆站经核准登记，准予执业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0082","BK0239","BK0028","BK0046","BK0168","BK0010","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313416","title":"天坛生物(600161.SH)下属浆站获得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313416","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665313416?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:36","pubTimestamp":1788773807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天坛生物 发布公告，公司控股子公司国药集团兰州生物制药有限公司下属皋兰兰生单采血浆有限责任公司、永登兰生单采血浆有限责任公司、甘谷兰生单采血浆有限责任公司、金塔兰生单采血浆有限责任公司收到甘肃省卫生健康委员会签发的《单采血浆许可证》，上述浆站经核准登记，准予执业。上述浆站获得《单采血浆许可证》，有利于扩大公司原料血浆采集规模，促进公司采浆量增长，对公司长期发展具有积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","600161","BK0185","BK0028","BK0010","BK0082","BK0046","BK0188","BK0168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005165","title":"开源证券：给予天坛生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663005165?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:01","pubTimestamp":1788181318,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对天坛生物进行研究并发布了研究报告《公司信息更新报告：2026上半年业绩承压，在研管线进展顺利》，给予天坛生物买入评级。已上市产品重组Ⅷ因子新增儿童适应症完成临床试验并通过临床现场核查。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为15.0。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663727080","title":"天坛生物（600161）披露2026年半年度报告，8月31日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663727080","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663727080?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:58","pubTimestamp":1788173896,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，天坛生物报收于12.24元，较前一交易日下跌0.81%，最新总市值为242.03亿元。该股当日开盘12.3元，最高12.42元，最低12.23元，成交额达9688.4万元，换手率为0.4%。近日，天坛生物披露《2026年半年度报告》。报告显示，公司总资产为17,045,482,603.93元，较上年度末增长2.79%；归属于上市公司股东的净资产为11,940,006,290.26元，同比增长1.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0188","BK0082","BK0185","BK0046","BK0168","BK0028","600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048627","title":"天坛生物（600161）2026年中报简析：净利润同比下降52.75%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048627?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:02","pubTimestamp":1788040975,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期天坛生物发布2026年中报。截至本报告期末，公司营业总收入25.95亿元，同比下降16.56%，归母净利润2.99亿元，同比下降52.75%。按单季度数据看，第二季度营业总收入14.54亿元，同比下降18.91%，第二季度归母净利润1.73亿元，同比下降55.45%。本报告期天坛生物应收账款上升，应收账款同比增幅达94.96%。去年的净利率为24.15%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于天坛生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701836","title":"图解天坛生物中报：第二季度单季净利润同比下降55.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663701836?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:39","pubTimestamp":1787938757,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物2026年中报显示，上半年度公司主营收入25.95亿元，同比下降16.56%；归母净利润2.99亿元，同比下降52.75%；扣非净利润2.85亿元，同比下降53.91%；其中2026年第二季度，公司单季度主营收入14.54亿元，同比下降18.91%；单季度归母净利润1.73亿元，同比下降55.45%；单季度扣非净利润1.71亿元，同比下降54.74%；负债率8.65%，投资收益785.82万元，财务费用65.13万元，毛利率35.99%。财报数据概要请见下图:本文数据来源于天坛生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900004765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655780738","title":"股市必读：天坛生物（600161）7月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655780738?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:32","pubTimestamp":1785432730,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，天坛生物报收于12.83元，上涨2.15%，换手率0.81%，成交量15.98万手，成交额2.04亿元。董秘最新回复投资者： 公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0010","BK0168","BK0185","BK0188","600161","BK0082","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820555","title":"天坛生物：将持续完善研发全流程质量管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820555?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404718,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：优化细胞与基因治疗药品审评审批(征求意见稿)对天坛生物公司的研发有何影响？天坛生物回复：感谢您对公司的关注。公司将密切关注法规更新与监管导向，持续完善研发全流程质量管理体系，严守合规管理要求，明确研发品种临床价值定位，充分利用法规创新政策加速成果转化。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0082","BK0168","BK0046","BK0188","BK0185","BK0010","600161","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655322820","title":"天坛生物：公司未开展相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655322820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655322820?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404718,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘先生，贵公司有无开展人类寿命延长的生物制品？目前全球顶尖生物技术研究发现，人类血液中存在长生因子，通过提炼，可以实现人类的身体机能年轻化。天坛生物回复：感谢您对公司的关注。公司未开展相关工作。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0082","600161","BK0010","BK0046","BK0028","BK0239","BK0168","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354820","title":"天坛生物：第四代层析工艺10%浓度“静注人免疫球蛋白”已获上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354820","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354820?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:45","pubTimestamp":1785404713,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物(600161)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。天坛生物回复：感谢您对公司的关注。公司下属成都蓉生研制的第四代层析工艺 10%浓度“静注人免疫球蛋白” 已于2023年获得上市许可，目前正在积极开展相关产品的市场拓展工作。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","BK0028","BK0010","BK0168","600161","BK0082","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745926","title":"天坛生物：公司应收账款风险均可控","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745926?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:57","pubTimestamp":1784800641,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。价格战何时见底？\"脱浆\"技术能否兑现？管理层今年是否实现。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0185","BK0010","BK0168","BK0239","BK0188","BK0028","BK0082","600161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653399745","title":"天坛生物：2025年9月管理级别提升为二级公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2653399745","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653399745?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:45","pubTimestamp":1784799915,"startTime":"0","endTime":"0","summary":"2025年9月，国药集团将公司管理级别由三级公司提升为二级公司，公司战略地位、资源获取能力进一步提升，治理架构进一步优化，公司依托央企股东背景实现快速发展的优势显著增强。按照股权关系，中国生物技术股份有限公司为公司控股股东，中国医药集团有限公司为公司实际控制人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0010","600161","BK0168","BK0082","BK0239","BK0028","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745887","title":"天坛生物：夯实血源根基，力争采浆量达到3000吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745887?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:42","pubTimestamp":1784799734,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK0028","600161","BK0188","BK0046","BK0168","BK0239","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653743749","title":"天坛生物：2026年加大改革力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2653743749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653743749?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:36","pubTimestamp":1784799378,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。2026年，公司正在加大改革力度，重点围绕血源、营销、研发、管理等四个维度，多措并举推动效率提升，持续增强核心竞争力、盈利能力。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","BK0168","BK0188","BK0082","BK0010","600161","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653437127","title":"天坛生物：市值管理的核心是价值创造","url":"https://stock-news.laohu8.com/highlight/detail?id=2653437127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653437127?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:36","pubTimestamp":1784799370,"startTime":"0","endTime":"0","summary":"天坛生物的各管理层对如今的国企央企市值管理有何看法？市值管理的核心是价值创造，当前，血液制品行业正处于调整期，但长期利好的趋势没有改变；公司持续围绕主营业务，以价值创造为核心，并通过精益管理提升运营效率、加大现金分红力度、不断提高信息披露质量、加强投资者关系管理等方式，努力推动公司投资价值合理反映公司质量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0010","600161","BK0168","BK0082","BK0239","BK0028","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653743933","title":"天坛生物：持续推动国产血液制品在神经专科和老年科赛道纵深布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2653743933","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653743933?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:24","pubTimestamp":1784798667,"startTime":"0","endTime":"0","summary":"证券之星消息，天坛生物07月23日在投资者关系平台上答复投资者关心的问题。依托本次中欧学术交流会，天坛生物搭建起临床医疗机构、权威科研院所与血液制品企业协同对话的专业平台。未来，公司将持续深耕人血白蛋白、静注人免疫球蛋白的创新临床转化，持续推动国产血液制品在神经专科和老年科赛道纵深布局，满足患者用药需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300035656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0046","BK0168","BK0010","BK0082","600161","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791636337950,"stockEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0218},{"period":"3month","weight":0.0666},{"period":"6month","weight":-0.1352},{"period":"1year","weight":-0.3317},{"period":"ytd","weight":-0.2115}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京天坛生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"84920人(较上一季度减少3.72%)","perCapita":"23285股","listingDate":"1998-06-16","address":"北京市大兴区北京经济技术开发区博兴二路6号院8号楼521室","registeredCapital":"197737万元","survey":"　　北京天坛生物制品股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白、人免疫球蛋白、组织胺人免疫球蛋白、皮下注射人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ等。","listedPrice":4.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天坛生物,600161,天坛生物股票,天坛生物股票老虎,天坛生物股票老虎国际,天坛生物行情,天坛生物股票行情,天坛生物股价,天坛生物股市,天坛生物股票价格,天坛生物股票交易,天坛生物股票购买,天坛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}